Elliott D. Crouser, MD
473 W 12th Ave
Columbus, OH 43210
Phone: (614) 293-4925
Current OSU Appointments
Associate Professor, Pulm,Allergy,Crit Care & Sleep
In addition to running the Sarcoidosis Clinic at OSU, Dr. Crouser is the Section Chief for the Division of Pulmonary and Critical Care Medicine and Medical Director of the ICU at University Hospital East (an affiliate of The Ohio State University Medical Center in Columbus, OH). Under his leadership the ICU structure has been optimized to deliver outstanding care (below target length-of-stay; risk adjusted mortality consistently <0.5) while providing expanded services (e.g., new stroke and acute myocardial infarction initiatives, increasing census). He also serves as an Editor for Critical Care Medicine, the top-ranked journal specializing in critical care, and reviews or serves on editorial boards for more than 20 other journals. He has served on NIH study sections, including an ongoing temporary appointment to the Surgery Anesthesia and Trauma study section (for 3 consecutive cycles), and has also reviewed grants for the Society of Critical Care Medicine, Wellcome Trust (London) and other extramural funding agencies. Dr. Crouser is actively funded by extramural sources for over 15 years, including ongoing support from the NIH to investigate inflammatory diseases that involve the lungs and other organs in the context of acute and chronic illness. His laboratory is among the first to have identified mitochondria as critical mediators of cell and organ dysfunction in the setting of acute systemic inflammatory diseases, including sepsis. His genomic studies in the field of pulmonary sarcoidosis identified novel disease mechanisms and "biomarkers" of disease progression. Ongoing studies in these areas of research promise to provide targets for new treatments for these poorly understood diseases.
Dorinsky PM, Crouser ED. "Oxygen Delivery in Critically Ill Patients." Mediguide. no. Mediguide 4: 1-5. (January 1997.): -.
Crouser ED. "Therapeutic benefits of antioxidants during sepsis: is protection against oxidant-mediated tissue damage only half the story?." Critical Care Medicine. Vol. 32, no. 2. (February 2004.): 589-.
Crouser ED. "Therapeutic Benefits of Antioxidents During Sepsis: Is Protection Against Oxidant-Medicated Tissue Damage Only Half the Story?." Critical Care Med. (January 2004.): -.
Crouser ED. "Mitochondrial Dysfunction in Septic Shock and Multiple Organ Dysfunction Syndrome." Mitochondrion. Vol. 4, (January 2004.): 729-741.
Crouser E, Cook C, Julian M, Huff J. "Impaired mitochondrial function and structure in the liver during subacute sepsis." Proceedings of the 6th World Congress on Trauma, Shock, Inflammation and Sepsis. (January 2004.): 199-201.
Crouser ED. "Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome.." Mitochondrion. Vol. 4, no. 5-6. (September 2004.): 729-.
Fahy RJ, Crouser ED. "Summary of International Conference of the American Thoracic Sociey." Advances in Sepsis. Vol. 4, (January 2005.): 154-156.
O'Brien JM, Crouser ED. "35th Critical Care Congress of the Society of Critical Care Medicine." Advances in Sepsis. Vol. 5, (January 2006.): 120-122.
Hoffmann S, Crouser ED. "Mitochondrial Mechanisms if Organ Dysfunction During Sepsis." Advances in Sepsisq. Vol. 6, (January 2007.): 2-9.
Hussain SRA, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Viatchenko-Karpinski S, Dang VX, Kuppusamy P, Crouser E, Byrd JC, Grever MR. "Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium." Blood. no. 111. (January 2008.): 3190-3199.
Crouser E; Exline M; Knoell D; Wewers MD. "Sepsis: links between pathogen sensing and organ damage.." Current Pharmaceutical Design. Vol. 14, no. 19. (January 2008.): 1840-.
Knoell DL, Julian MW, Bao S, Besecker B, Huff JE, Leikauf G, DiSilvestro R, Crouser E. "Mortaligy is Significantly Increased by Zinc Deficiency in an Adult Murine Model of Polymicrobial Sepsis." Critical Care Medicine. no. 37. (January 2009.): 1380-1388.
Crouser E, Culver DA, Huff JE, Julian MW, Shao G, Liyanarachchi S, Knox KS, Macre JE, Wewers MD, Gavrilin M, Ross P, Abbas A, Eng C. "Gene Expression Profiling Identifies MMP-12 and ADAMDEC1 as Potential Pathogenic Mediators of Pulmonary Sarcoidosis." Am J Respir Critical Care Medicine. no. 179. (January 2009.): 929-938.
Knoell DL; Julian MW; Bao S; Besecker B; Macre JE; Leikauf GD; DiSilvestro RA; Crouser ED. "Zinc deficiency increases organ damage and mortality in a murine model of polymicrobial sepsis.." Critical Care Medicine. Vol. 37, no. 4. (April 2009.): 1380-.
Rosenbaum JT, Pasadhika S, Crouser E, Harrington CA, Choi D, Smith JR, Braziel RM, Vance EE, Planck SR. "Hypothesis: Sarcoidosis is a STAT1-mediated disease." Clinical Immunology. no. 132. (January 2009.): 174-183.
Pompili VJ; Crouser ED. "Stem cell therapy: A "magic bullet" for cardiomyopathies?." Critical Care Medicine. Vol. 37, no. 4. (April 2009.): 1487-.
Crouser E, Lozanski G, Fox CC, Hauswirth DW, Raveendran R, Julian MW. "The CD4+lymphopeni sarcoidosis phenotype is highly responsive to anti-TNF therap." Chest. no. 137. (January 2010.): 1432-1435.
Crouser ED. "Peroxisome proliferator-activated receptors gamma coactivator-1alpha: master regulator of mitochondrial biogenesis and survival during critical illness?." American Journal Of Respiratory And Critical Care Medicine. Vol. 182, no. 6. (September 2010.): 726-.
Nana-Sinkam SP; Crouser ED. "Altered immune surveillance: a common link between cancer and sepsis?." Critical Care Medicine. Vol. 38, no. 3. (March 2010.): 1000-.
|January 2006||Lucas, D. M.; Hussain, S. R. A.; Johnson, A. J.; Smith, L. L.; Wagner, A. J.; Allison, J. M.; Guster, S. E.; Lin, T. S.; Byrd, J. C.; Julian, M. W.; Crouser, E. D.; Grever, M. R.."Flavopiridol decreases Mcl-1 and initiates early mitochondrial damage in chronic lymphocytic leukemia (CLL) cells" . : 595A|
|January 2007||Shao, G.; Julian, M. W.; Huff, J. E.; Wewers, M. D.; Shadel, G. S.; Crouser, E. D.."Highly purified high mobility group proteins do not directly activate peripheral blood monocytes" . : A447|
|January 2007||Crouser, E. D.; Huff, J. E.; Wewers, M. D.; Knox, K. S.; Ross, P.; Abbas, A.; Eng, C.."Analysis of lung gene expression in sarcoidosis and granulomatous infections" . : A185|
|January 2007||Knoell, D. L.; Julian, M. W.; Bao, S.; Huff, J. E.; Crouser, E. D.."Sepsis mortality is dramatically increased in zinc deficient mice" . : A437|
|January 2008||Pasadhika, S.; Crouser, E. D.; Harrington, C. A.; Choi, D.; Planck, S. R.; Smith, J. R.; Rosenbaum, J. T.."Microarray gene expression profile of peripheral blood from patients with Sarcoidosis implicates the transcription factor, STAT1" .|
|November 2008||Raveendran, R.; Hauswirth, D. W.; Crouser, E. D.; Fox, C. C.."Sarcoidosis patients with profound CD4 lymphopenia and opportunistic infections" Seattle.|
|November 2009||Erdal, S.; Clymer, B.; Crouser, E. D.."Developing CAD tools for measuring sarcoidosis: Leveraging existing data from a personalized health care perspective" Chicago.|
|November 2009||Erdal, S.; Catalyurek, U.; Krishnamurthy, A.; Kamal, J.; Crouser, E. D.; Clymer, B.."3D haralick texture analysis using CUDA" Chicago.|
|May 2009||Crouser, E. D.; Julian, M. W.; Shao, G.; Fox, C. C.; Hauswirth, D. W.; Jehn, J. J.; Lozanski, G.; Erdal, S.; Wewers, M. D.."Infliximab reverses peripheral CD4+ T cell depletion in lymphopenic Sarcoidosis patients" San Diego.|
|May 2010||Thacker, M.; Aguda, B.; Crouser, E. D.."In silico modeling of sarcoidosis granuloma formation implicates TNF alpha and regulatory T cells (Tregs) as critical therapeutic targets" New Orleans.|
|May 2010||Crouser, E. D.; Shao, G.; Julian, M. W.; Bao, S.."PI-3K is essential for plasmacytoid dendritic cell type I IFN responses to mitochondrial transcription factor A (TFAM) and CpG DNA" San Diego.|
|May 2010||Crouser, E. D.; Julian, M. W.; Shao, G.."Mitochondrial antigens are selectively recognized by TLR-2 in the context of cell necrosis" New Orleans.|